Everest Medicines (HKG:1952) obtained approval for the new drug application of CARDAMYST from China's National Medical Products Administration.
The drug is for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults, according to a Thursday Hong Kong bourse filing.